1. PI3K/Akt/mTOR
    Stem Cell/Wnt
  2. GSK-3

AZD1080 

Cat. No.: HY-13862 Purity: 99.10%
Handling Instructions

AZD1080 is a potent and selective GSK3 inhibitor. AZD1080 inhibits recombinant human GSK3α and GSK3β with pKi (IC50) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.

For research use only. We do not sell to patients.
AZD1080 Chemical Structure

AZD1080 Chemical Structure

CAS No. : 612487-72-6

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 290 In-stock
5 mg USD 264 In-stock
10 mg USD 420 In-stock
50 mg USD 1026 In-stock
100 mg USD 1596 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

AZD1080 is a potent and selective GSK3 inhibitor. AZD1080 inhibits recombinant human GSK3α and GSK3β with pKi (IC50) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.

IC50 & Target

IC50: 6.9 nM (GSK3α), 31 nM (GSK3β)[1]
pKi: 8.2 (GSK3α), 7.5 (GSK3β)[1]

In Vitro

AZD1080 shows selectivity against cdk2 (pKi=5.9; 1150 nM; 37-fold), cdk5 (pKi=6.4; 429 nM; 14-fold), cdk1 (pKi=5.7; 1980 nM; 64-fold) and Erk2 (pKi< 5; >10 μM; >323-fold). AZD1080 (at 10 μM) is also evaluated for pan-kinase selectivity and showed good overall selectivity versus 23 kinases, as well as against 65 different receptors, enzymes and ion channels in MDS Pharma screen (< 50% effect at 10 μM AZD1080). Concentration-dependent inhibition of tau phosphorylation is observed for AZD1080 (IC50=324 nM) and the non-selective reference GSK3 inhibitor LiCl (IC50=1.5 mM) indicating that AZD1080 is several orders of magnitude more potent than LiCl[1].

In Vivo

The pharmacokinetic analysis in blood after oral administration revealed that AZD1080 has a good oral bioavailability in rats (15-24%) with a half-life of 7.1 h, making AZD1080 attractive for further in vivo testing. The subchronic (3 days) oral treatment with AZD1080 at 4 or 15 μmol/kg significantly blocked the MK-801-induced memory deficit (AZD1080 vs. MK-801, p<0.05 at 4 μmol/kg and p<0.01 at 15 μmol/kg) in mice, raising the hypothesis that longer treatment may be required to prime the synapses to function effectively[1].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.9907 mL 14.9535 mL 29.9070 mL
5 mM 0.5981 mL 2.9907 mL 5.9814 mL
10 mM 0.2991 mL 1.4953 mL 2.9907 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[1]

The GSK3β, Cdk2, and Cdk5 Ki’s are determined using scintillation proximity assays and kinetic analyses. The GSK3α assay is performed for the GSK3β assay. The KM value of ATP used to calculate the Ki value for GSKα is 10 μM. Inhibition of Cdk1 is performed. The KM value of ATP used to calculate the Ki value is 51 μM. Erk2 activity is determined using an Ser/Thr kinase SPA kit, p42 MAPK kinase (20 U/well), and biotinylated MBP. The KM value of ATP used to calculate the Ki value is 71 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

AZD1080 is prepared in water with 0.5% ascorbic acid, 0.01% EDTA, pH 2.0 (Mice and Rats)[1].

Mice[1]
A total of 161 male C57BL/6 mice, 8-12 weeks of age, are used. The animals are kept in conventional housing (3-5 mice per cage) and fed standard rodent chew and tap water ad libitum. Typically 9-12 mice are included in each experimental group and 2-4 mice in the satellite groups (for determination of compound exposure in plasma and brain, see below). AZD1080 (4.0 or 15 μmol/kg) or vehicle (water with 0.5% ascorbic acid, 0.01% EDTA, pH 2.0) is administered by oral gavage (10 mL/kg) acutely or subchronically (twice daily) for 3 days. The training trial is performed at 1.5, 3, or 5 h after final administration with AZD1080. To disrupt learning, the mice received subcutaneous administration of MK-801 (0.1 or 0.15 mg/kg; (+)-MK.801 hydrogen maleate) or vehicle (saline) 30 min before the training trial.
Rats[1]
A total of 71 adult male Sprague-Dawley rats (250-300 g) are used. The rats receive an acute dose of AZD1080 (1, 3 or 10 μmol/kg) or vehicle (water with 0.5% ascorbic acid, 0.01% EDTA, pH 2.0) via oral gavage (dosing volume 5 mL/kg). At 1, 2, 3, 6, or 24 h after administration the rats are anesthetized and blood, from abdominal aorta, is sampled in heparin micro tainer tubes. Peripheral blood mononuclear cells (PBMC) are isolated from the blood samples. Separate blood samples are obtained for plasma processing and subsequent bioanalysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

334.37

Formula

C₁₉H₁₈N₄O₂

CAS No.

612487-72-6

SMILES

OC(N1)=C(C2=CC=C(CN3CCOCC3)C=N2)C4=C1C=CC(C#N)=C4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 21.35 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.10%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
AZD1080
Cat. No.:
HY-13862
Quantity: